HK1125673A1 - Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo - Google Patents
Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoInfo
- Publication number
- HK1125673A1 HK1125673A1 HK09103538.4A HK09103538A HK1125673A1 HK 1125673 A1 HK1125673 A1 HK 1125673A1 HK 09103538 A HK09103538 A HK 09103538A HK 1125673 A1 HK1125673 A1 HK 1125673A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vivo
- life
- fusion proteins
- recombinant human
- human epo
- Prior art date
Links
- 230000000913 erythropoietic effect Effects 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 238000001727 in vivo Methods 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/340,661 US7625564B2 (en) | 2006-01-27 | 2006-01-27 | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
PCT/CA2007/000107 WO2007085084A1 (en) | 2006-01-27 | 2007-01-25 | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1125673A1 true HK1125673A1 (en) | 2009-08-14 |
Family
ID=38308802
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09103538.4A HK1125673A1 (en) | 2006-01-27 | 2009-04-17 | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
HK12111281.1A HK1170507A1 (en) | 2006-01-27 | 2012-11-08 | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo epo-fc |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12111281.1A HK1170507A1 (en) | 2006-01-27 | 2012-11-08 | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo epo-fc |
Country Status (21)
Country | Link |
---|---|
US (8) | US7625564B2 (xx) |
EP (2) | EP2450373B1 (xx) |
JP (3) | JP5222153B2 (xx) |
KR (2) | KR20120014936A (xx) |
CN (3) | CN102816242B (xx) |
AU (1) | AU2007209722B2 (xx) |
BR (1) | BRPI0706742C1 (xx) |
CA (1) | CA2650072C (xx) |
DK (2) | DK1994157T3 (xx) |
ES (2) | ES2539778T3 (xx) |
HK (2) | HK1125673A1 (xx) |
IL (1) | IL192801A (xx) |
MX (1) | MX2008009322A (xx) |
NZ (1) | NZ569702A (xx) |
PL (2) | PL2450373T3 (xx) |
PT (2) | PT2450373E (xx) |
RU (1) | RU2433181C2 (xx) |
SG (2) | SG169351A1 (xx) |
TW (1) | TWI454482B (xx) |
WO (1) | WO2007085084A1 (xx) |
ZA (1) | ZA200805920B (xx) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1759001T3 (da) * | 2004-04-21 | 2011-08-01 | Enobia Pharma Inc | Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen |
US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
JP4356902B2 (ja) * | 2006-12-28 | 2009-11-04 | 信広 益子 | 歯ブラシ |
WO2009012600A1 (en) * | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins |
EP2391714B2 (en) | 2009-01-30 | 2019-07-24 | Whitehead Institute for Biomedical Research | Methods for ligation and uses thereof |
CA2753438A1 (en) * | 2009-02-24 | 2010-09-02 | Alexion Pharmaceuticals, Inc. | Antibodies containing therapeutic tpo/epo mimetic peptides |
US20110016548A1 (en) * | 2009-07-16 | 2011-01-20 | University Of Southern California | Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems |
EP2563406A4 (en) | 2010-04-30 | 2013-11-13 | Alexion Pharma Internat Sarl | METHOD, COMPOSITIONS AND KITS FOR TREATING MATRIX MINERALIZATION DISORDERS |
CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术(上海)有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
JP6055779B2 (ja) | 2010-12-27 | 2016-12-27 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ナトリウム利尿ペプチドを含む組成物およびその使用方法 |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
CN103917563A (zh) | 2011-06-28 | 2014-07-09 | 英伊布里克斯有限责任公司 | 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法 |
WO2013013613A1 (zh) | 2011-07-25 | 2013-01-31 | 健能隆医药技术(上海)有限公司 | G-csf二聚体在制备治疗神经退行性疾病药物中的应用 |
EP2561888A1 (en) * | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protein comprising NC-1 for treating angiogenesis-related diseases |
WO2013027191A1 (en) * | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
KR101183615B1 (ko) * | 2011-12-28 | 2012-09-17 | 재단법인 경기과학기술진흥원 | Wnt에 결합하는 신규한 재조합 단백질 |
JP5836402B2 (ja) * | 2012-01-25 | 2015-12-24 | Sbiファーマ株式会社 | 腫瘍診断剤 |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
EP2892919A1 (en) * | 2012-09-07 | 2015-07-15 | Sanofi | Fusion proteins for treating a metabolic syndrome |
WO2014093387A1 (en) * | 2012-12-10 | 2014-06-19 | Kindred Biosciences, Inc. | Vegf receptor fusion proteins for veterinary use |
AR096890A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
RU2563175C1 (ru) * | 2014-06-03 | 2015-09-20 | государственное бюджетное образовательное учреждение высшего профессионального образования "Тюменская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ТюмГМА Минздрава России) | Способ стимуляции эритропоэза в предоперационном периоде |
US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
EP3194429A4 (en) * | 2014-09-18 | 2018-06-13 | Askgene Pharma, Inc. | Novel feline erythropoietin receptor agonists |
RU2708068C2 (ru) | 2014-12-05 | 2019-12-04 | Алексион Фармасьютикалз, Инк. | Лечение судорог с использованием рекомбинантной щелочной фосфатазы |
US11524054B2 (en) * | 2015-01-09 | 2022-12-13 | Genexine, Inc. | Method of treating anemia using long-acting EPO formulation |
US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
WO2016178087A1 (en) | 2015-05-04 | 2016-11-10 | Biosourcing Sa | Transgenic production of chorionic gonadotropin |
EP3291670A1 (en) | 2015-05-04 | 2018-03-14 | Laboratoire Français du Fractionnement et des Biotechnologies | Transgenic production of fc fusion proteins |
RU2745528C2 (ru) | 2015-08-17 | 2021-03-26 | Алексион Фармасьютикалз, Инк. | Производство щелочных фосфатаз |
EP3355904A4 (en) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA |
CN105111315B (zh) * | 2015-09-29 | 2018-05-22 | 海南医学院 | MIP3α-Fc融合蛋白及其用途 |
KR101847169B1 (ko) * | 2015-10-07 | 2018-04-09 | 주식회사 녹십자 | 지속형 에리트로포이에틴 함유 조성물 |
US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
EP3377520A4 (en) * | 2015-11-16 | 2019-11-06 | Ubiprotein, Corp. | METHOD FOR EXTENDING THE HALF-LIFE OF A PROTEIN |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
WO2017173413A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
JP7018933B2 (ja) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 気管気管支軟化症の治療方法 |
WO2018105988A1 (ko) * | 2016-12-05 | 2018-06-14 | 한미약품 주식회사 | 면역반응이 약화된 결합체 |
CA3057502A1 (en) | 2017-03-31 | 2018-10-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (hpp) in adults and adolescents |
WO2018203582A1 (ko) * | 2017-05-05 | 2018-11-08 | 주식회사 유비프로틴 | 단백질 반감기를 증가시키는 방법 |
CN110078817B (zh) * | 2018-01-26 | 2021-02-19 | 重庆精准生物技术有限公司 | 一种改良的铰链区及其在构建car骨架中的应用 |
JP2021519590A (ja) | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 糖タンパク質の製造 |
WO2020053661A1 (en) | 2018-09-13 | 2020-03-19 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Methods of purifying antibodies from the milk of transgenic non-human mammals comprising the use of chitosan |
RU2696864C1 (ru) * | 2018-09-24 | 2019-08-07 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики нарушений микроциркуляции в почках асиалированным эритропоэтином в эксперименте |
RU2678768C1 (ru) * | 2018-09-25 | 2019-02-01 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте |
CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
WO2021251438A1 (ja) * | 2020-06-10 | 2021-12-16 | 株式会社バイカ・セラピュティクス | エリスロポエチンポリペプチドを含む融合タンパク質 |
US20230265407A1 (en) * | 2020-07-02 | 2023-08-24 | Northwestern University | Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects |
CN111704676A (zh) * | 2020-07-17 | 2020-09-25 | 上海延立药业有限公司 | 一种长效重组促红细胞生成素及其制备方法和应用 |
WO2022080912A1 (ko) * | 2020-10-16 | 2022-04-21 | 주식회사 아이엠바이오로직스 | IgM 영역을 이용한 융합단백질 플랫폼 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
ES2251009T3 (es) | 1990-06-28 | 2006-04-16 | Sanofi-Aventis Deutschland Gmbh | Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso. |
US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
ITFI940106A1 (it) | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
WO1996018412A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US7696338B2 (en) | 1995-10-30 | 2010-04-13 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin fusion proteins and means for expression thereof |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
WO1999002709A1 (en) | 1997-07-10 | 1999-01-21 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
EP1088888A4 (en) | 1998-05-14 | 2005-03-16 | Merck Patent Gmbh | MERGED PROTEIN |
US20050181482A1 (en) | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
ES2273497T3 (es) | 1998-06-15 | 2007-05-01 | Gtc Biotherapeutics, Inc. | Proteina de fusion de la albumina serica humana de eritropoyetina analoga. |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
DE60040225D1 (en) | 1999-07-13 | 2008-10-23 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
AU1226901A (en) | 1999-10-22 | 2001-05-08 | Amgen, Inc. | Biodegradable microparticles with novel erythropoietin stimulating protein |
EP1228214A2 (en) * | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietin forms with improved properties |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
DK1274728T3 (da) | 2000-04-21 | 2008-09-01 | Amgen Inc | Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi |
JP3946638B2 (ja) | 2000-12-11 | 2007-07-18 | シージェイ コーポレーション | 生体内エリスロポエチン活性が増強された融合蛋白質 |
EP2706116A1 (en) | 2001-01-17 | 2014-03-12 | Emergent Product Development Seattle, LLC | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
BR0207854A (pt) * | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
US6797493B2 (en) | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
KR100467750B1 (ko) | 2001-11-29 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
KR100467751B1 (ko) | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
US20040063912A1 (en) | 2002-03-15 | 2004-04-01 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
CA2479212A1 (en) | 2002-03-15 | 2003-09-25 | Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
DE10227606B3 (de) | 2002-06-20 | 2004-01-22 | Bionethos Holding Gmbh | Verwendung von Thrombopoietin zur Kultivierung von Hepatozyten |
AU2003232081B2 (en) | 2002-07-03 | 2009-02-05 | Brandeis University | Central airway administration for systemic delivery of therapeutics |
EP1578447A4 (en) | 2002-10-31 | 2009-06-03 | Genentech Inc | METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION |
US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
ES2315664T3 (es) * | 2003-06-30 | 2009-04-01 | Domantis Limited | Anticuerpos de dominio unico (dab) pegilados. |
WO2005027966A2 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
RU2370276C2 (ru) | 2003-12-31 | 2009-10-20 | Мерк Патент Гмбх | Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ |
EP1586585A1 (de) * | 2004-04-14 | 2005-10-19 | F. Hoffmann-La Roche Ag | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung |
CA2595679A1 (en) | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes |
EP1966237A2 (en) | 2005-11-24 | 2008-09-10 | Laboratoires Serono SA | Erythropoietin polypeptides and uses thereof |
US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
WO2009012600A1 (en) * | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins |
-
2006
- 2006-01-27 US US11/340,661 patent/US7625564B2/en active Active
-
2007
- 2007-01-25 DK DK07719348.0T patent/DK1994157T3/da active
- 2007-01-25 KR KR1020117031687A patent/KR20120014936A/ko active Search and Examination
- 2007-01-25 MX MX2008009322A patent/MX2008009322A/es active IP Right Grant
- 2007-01-25 CN CN201210211118.XA patent/CN102816242B/zh active Active
- 2007-01-25 CA CA2650072A patent/CA2650072C/en active Active
- 2007-01-25 WO PCT/CA2007/000107 patent/WO2007085084A1/en active Application Filing
- 2007-01-25 PT PT121532329T patent/PT2450373E/pt unknown
- 2007-01-25 PL PL12153232T patent/PL2450373T3/pl unknown
- 2007-01-25 SG SG201100553-5A patent/SG169351A1/en unknown
- 2007-01-25 NZ NZ569702A patent/NZ569702A/en unknown
- 2007-01-25 EP EP12153232.9A patent/EP2450373B1/en active Active
- 2007-01-25 US US12/162,320 patent/US10117949B2/en active Active
- 2007-01-25 ES ES12153232.9T patent/ES2539778T3/es active Active
- 2007-01-25 SG SG10201404308RA patent/SG10201404308RA/en unknown
- 2007-01-25 DK DK12153232.9T patent/DK2450373T3/da active
- 2007-01-25 PT PT77193480T patent/PT1994157E/pt unknown
- 2007-01-25 ES ES07719348.0T patent/ES2539759T3/es active Active
- 2007-01-25 BR BRPI0706742A patent/BRPI0706742C1/pt active IP Right Grant
- 2007-01-25 EP EP07719348.0A patent/EP1994157B1/en active Active
- 2007-01-25 CN CN2007800004392A patent/CN101321870B/zh active Active
- 2007-01-25 RU RU2008134389/10A patent/RU2433181C2/ru active
- 2007-01-25 AU AU2007209722A patent/AU2007209722B2/en active Active
- 2007-01-25 CN CN201210004888.7A patent/CN102516399B/zh active Active
- 2007-01-25 PL PL07719348T patent/PL1994157T3/pl unknown
- 2007-01-25 JP JP2008551610A patent/JP5222153B2/ja active Active
- 2007-01-25 KR KR1020087021042A patent/KR101235124B1/ko active IP Right Grant
- 2007-07-20 TW TW096126612A patent/TWI454482B/zh active
-
2008
- 2008-07-08 ZA ZA200805920A patent/ZA200805920B/xx unknown
- 2008-07-14 IL IL192801A patent/IL192801A/en active IP Right Grant
-
2009
- 2009-04-17 HK HK09103538.4A patent/HK1125673A1/xx unknown
- 2009-09-08 US US12/555,742 patent/US7964375B2/en active Active
- 2009-09-08 US US12/555,743 patent/US8431132B2/en active Active
-
2012
- 2012-11-08 HK HK12111281.1A patent/HK1170507A1/xx unknown
- 2012-12-06 JP JP2012267451A patent/JP6103579B2/ja active Active
-
2013
- 2013-04-29 US US13/872,790 patent/US9375487B2/en active Active
-
2015
- 2015-09-14 JP JP2015180997A patent/JP2016006116A/ja active Pending
-
2016
- 2016-06-27 US US15/194,306 patent/US10233223B2/en active Active
-
2018
- 2018-05-29 US US15/992,068 patent/US11279742B2/en active Active
-
2022
- 2022-03-21 US US17/700,251 patent/US20230265143A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1170507A1 (en) | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo epo-fc | |
IL266122A (en) | Stable serum-free cell-to-cell gene transfer and production of recombinant human proteins in human cell lines | |
EP2007884A4 (en) | ENZYMATIC FUSION PROTEINS AND THEIR USE | |
IL188420A0 (en) | Methods and compositions with enhanced therapeutic activity | |
IL184763A0 (en) | Conjugates of biologically active proteins having a modified in vivo half-life | |
EP2173377A4 (en) | ANTIBODY-ENDOSTATIN FUSION PROTEIN AND ITS VARIANTS | |
EP1877090A4 (en) | OX-40 IMMUNOGLOBULINIC TRIMER FUSION PROTEIN AND METHODS OF USE | |
ZA200707413B (en) | Cat allergen fusion proteins and uses thereof | |
IL176895A0 (en) | Purified interleukin-15/fc fusion protein and preparation thereof | |
EP2102237A4 (en) | RECOMBINANT HUMAN FACTOR IX AND USE THEREOF | |
EP1871793A4 (en) | PROTOONCOGEN HUMAN AND PROTEIN CODED THEREWITH | |
EP2223999A4 (en) | EPHA4 POLYPEPTIDE WITH NEW ACTIVITY AND USE THEREOF | |
ATE460483T1 (de) | Fusionsprotein mit gesteigerter in vivo erythropoietin-aktivität | |
GB0516058D0 (en) | New protein isoforms and uses thereof | |
IL198659A (en) | Targeted signals and recombinant proteins containing them | |
ZA200804095B (en) | Nucleic acids and proteins associated with galactomannan synthesis in coffee | |
ZA200606216B (en) | Modified human interferon polypeptides and their uses | |
EP1937294A4 (en) | GLYCOLIC AND GLYCOSYLATED THERAPEUTIC PROTEINS DERIVED FROM POULTRY | |
ZA200707006B (en) | Conjugates of biologically active proteins having a modified in vivo half-life | |
EP1838728A4 (en) | HUMAN PROTOONKOGEN AND THE CODED PROTEIN | |
IL192400A0 (en) | Novel polypeptide having esterase activity and recombinant esterase and use thereof | |
IL188824A (en) | Plant cells expressing recombinant human glucosrybridosidase and their use as a drug | |
GB0522667D0 (en) | New protein isoforms and uses thereof | |
IL183341A0 (en) | Lupac polypeptide, its preparation and use in protein production |